Oncternal Therapeutics
12230 El Camino Real
Suite 300
San Diego
CA
92130
United States
Tel: (858) 434 1113
Website: http://www.oncternal.com/
37 articles about Oncternal Therapeutics
-
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
2/29/2024
Oncternal Therapeutics, Inc. announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024.
-
Oncternal Therapeutics Announces Reverse Stock Split - Jan 04, 2024
1/4/2024
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that its board of directors has approved a 1-for-20 reverse stock split of the company's common stock.
-
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager.
-
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
12/26/2023
Oncternal Therapeutics, Inc. updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.
-
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
8/10/2023
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported second quarter 2023 financial results.
-
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - June 30, 2023
6/30/2023
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is joining Oncternal as VP, Clinical Development.
-
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
5/4/2023
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported first quarter 2023 financial results.
-
Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors
4/13/2023
Oncternal Therapeutics, Inc. announced that two key industry opinion leaders and management will participate in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m.
-
The money saved on canceling the existing studies is intended to fund the advancement of two other oncology pipeline assets.
-
Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025
4/3/2023
Oncternal Therapeutics, Inc. announced a strategic reprioritization based on the rapidly changing commercial landscape for Bruton’s tyrosine kinase inhibitors.
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2023
3/1/2023
Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Yelena Tsabur, who joined Oncternal as Associate Clinical Trial Manager.
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023
2/1/2023
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Jennifer Neumann, who joined Oncternal as Director, Clinical Data Management.
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023
1/3/2023
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted inducement awards to two new non-executive employees.
-
Combinations including Ibrutinib stood out in hard-to-treat hematological cancers at the 64th American Society of Hematology (ASH) annual meeting.
-
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
12/10/2022
Oncternal Therapeutics, Inc. announced updated interim clinical data from ongoing Phase 1/2 Study CIRM-0001 in an oral presentation at the American Society of Hematology 2022 Annual Meeting.
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - November 14, 2022
11/14/2022
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Edward C. Dow, who joined Oncternal as Vice President, Clinical Development.
-
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022
11/3/2022
Oncternal Therapeutics, Inc. announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented in an Oral Session at the American Society of Hematology Annual Meeting and Exposition taking place on December 10-13, 2022, in New Orleans, Louisiana.
-
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
11/3/2022
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported financial results for the third quarter of 2022.
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022
10/3/2022
Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Ariadne Jerue, who joined Oncternal as Associate Director, Clinical Operations.
-
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma
10/3/2022
Oncternal Therapeutics, Inc. announced the receipt of a ‘Study May Proceed’ letter from the U.S. Food and Drug Administration, 30 days after submitting its Investigational New Drug application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin’s lymphoma, including those who have failed previous CD19 CAR T treatment.